Citius Pharmaceuticals - Public Comps and Valuation Multiples

Citius Pharmaceuticals Overview

About Citius Pharmaceuticals

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Founded

2007

HQ

Employees

Website

citiuspharma.com

Sectors

Drug Development & Therapeutics
Regenerative Medicine
BioTech

Financials

LTM Revenue $19.7M

Last FY EBITDA -$38.2M

EV

$15.4M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Citius Pharmaceuticals Financials

As of December 2025, Citius Pharmaceuticals reported last 12-month revenue of $19.7M.

In the same period, Citius Pharmaceuticals achieved -$18.9M in LTM net income.

See Citius Pharmaceuticals valuation multiples based on analyst estimates

Citius Pharmaceuticals P&L

In the most recent fiscal year, Citius Pharmaceuticals reported EBITDA of -$38.2M.

Citius Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Citius Pharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$19.7M	XXX	n/a	XXX	XXX	XXX
Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	n/a	XXX	-$38.2M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBIT	-$12.4M	XXX	-$38.5M	XXX	XXX	XXX
EBIT Margin	-63%	XXX	n/a	XXX	XXX	XXX
Net Profit	-$18.9M	XXX	-$37.4M	XXX	XXX	XXX
Net Margin	-96%	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Citius Pharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $19.7M.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$19.7M	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	-$38.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$12.4M	Analyst estimates available to subscribers	-$38.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-62.9% EBIT margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$18.9M	Analyst estimates available to subscribers	-$37.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-95.8% net profit margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Citius Pharmaceuticals

This financial data table provides comprehensive performance metrics for Citius Pharmaceuticals, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Citius Pharmaceuticals generated $19.7M in revenue over the last twelve months.
Net income over the last twelve months reached -$18.9M.

Fiscal Year Performance

Fiscal year EBITDA was -$38.2M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Citius Pharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Citius Pharmaceuticals Stock Performance

Citius Pharmaceuticals has current market cap of $17.8M, and EV of $15.4M.

Market Cap Evolution

Citius Pharmaceuticals Stock Data

As of January 16, 2026, Citius Pharmaceuticals's stock price is $1.

See Citius Pharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$15.4M	$17.8M	XXX	XXX	XXX	XXX	$-2.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Citius Pharmaceuticals Valuation Multiples

Citius Pharmaceuticals's trades at n/a EV/Revenue multiple, and -0.4x EV/EBITDA.

See valuation multiples for Citius Pharmaceuticals and 15K+ public comps

Citius Pharmaceuticals Financial Valuation Multiples

As of January 16, 2026, Citius Pharmaceuticals has market cap of $17.8M and EV of $15.4M.

Equity research analysts estimate Citius Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Citius Pharmaceuticals has a P/E ratio of -0.9x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$17.8M	XXX	$17.8M	XXX	XXX	XXX
EV (current)	$15.4M	XXX	$15.4M	XXX	XXX	XXX
EV/Revenue	0.8x	XXX	n/a	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-0.4x	XXX	XXX	XXX
EV/EBIT	-1.2x	XXX	-0.9x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-0.9x	XXX	-0.9x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-0.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Citius Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Citius Pharmaceuticals Margins & Growth Rates

Citius Pharmaceuticals's last 12 month revenue growth is 380%

Citius Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.7M for the same period.

Citius Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Citius Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Citius Pharmaceuticals and other 15K+ public comps

Citius Pharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	380%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.7M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial